Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How US Can Learn From Biosimilar Implementation In EU

This article was originally published in The Pink Sheet Daily

Executive Summary

Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.

You may also be interested in...



RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings

Another rosy report foresees massive savings over the next decade, but RAND acknowledges that many factors will be the true determinants of spending decreases from biosimilars.

RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings

Another rosy report foresees massive savings over the next decade, but RAND acknowledges that many factors will be the true determinants of spending decreases from biosimilars.

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel